Back to Top Skip to main content Skip to sub-navigation

Understanding the potential of COVID-19 convalescent plasma

Researcher scans a unit of plasma in lab. U.S. Army Sgt. Reginald Miles labels donated liquid plasma at the Landstuhl Blood Donor Center. Researchers are studying COVID-19 convalescent plasma to harness the power of neutralizing antibodies to help patients. (Photo by Volker Ramspott)

Recommended Content:

Coronavirus | Convalescent Plasma Collection Program | Armed Services Blood Program

The Department of Defense has set a goal to collect more than 8,000 donated units of plasma from patients who have recovered from COVID-19 by Sept. 30, 2020. This blood will be used to treat critically ill patients and support the development of an effective treatment against the disease.

Like a missile locking on its target, antibodies attack invaders inside the body with a singularity of purpose: search and destroy. Typically, infection-fighting white blood cells produce antibodies as an appropriate response to an invading germ. In some people whose immune systems can’t mount a sufficient attack against a virus, donated antibodies from another person’s plasma may help. Researchers believe the power of antibodies lies in their ability to bind to a virus and neutralize it, or block it from entering cells, said Dr. Kayvon Modjarrad, director of the Emerging Infectious Diseases Branch at the Walter Reed Army Institute of Research in Silver Spring, Maryland. Modjarrad leads the Army’s COVID-19 vaccine development research.

But not all antibodies are created the same. “Antibodies come in different flavors, some of them are neutralizing and some of them are non-neutralizing and we don’t know exactly which individuals are developing what type of antibody,” said Shelly Krebs, chief of B Cell Biology Core at WRAIR Military HIV Research program.

COVID-19 convalescent plasma, or CCP, from a recovered patient could be a mixture of both neutralizing and non-neutralizing antibodies. In fact, people infected with COVID-19 can have varying antibody responses. Some may not have enough antibodies in their plasma to benefit another patient, which is why CCP first needs to be tested for neutralizing antibody levels before transfusing, explained Modjarrad. His lab works to understand the mechanism of COVID-19 antibodies to predict the levels required to offer a person protection from the virus.

Transfusing antibodies provides short-term immunity as the donor antibodies last several weeks to months inside the body, said Navy Capt. (Dr.) Todd Gleeson of the Navy Bloodborne Infection Management Center, located at Naval Support Activity Bethesda, Maryland. “It is likely that a person with COVID-19 who receives CCP will also still develop their own immune cells and produce antibodies to fight the virus if that person is re-exposed in the future,” said Gleeson, who leads a convalescent plasma study of patients at Walter Reed National Military Medical Center also at NSAB in Bethesda. But scientists just can’t confirm that yet. They hope to uncover the answer and many more as they study CCP and COVID-19 antibodies to better treat patients and develop future vaccines.

Military medical treatment facilities will soon take part in an observational study across the Department of Defense to help researchers track trends among patients with COVID-19. The data will help trace recovered patients to ask for CCP donations as the DoD seeks to build a storehouse of CCP for patients admitted to Military Health System facilities and those deployed outside the U.S., explained Army Col. (Dr.) Andrew Cap, director of research at the Army Institute of Surgical Research in San Antonio, Texas. “The goal is to build a convalescent plasma capability within the DoD, both on the collection and on the treatment side,” said Cap, who helped draft a CCP protocol for the DoD.

Future research may lead to the development of highly concentrated neutralizing antibodies extracted from large quantities of convalescent plasma as a potential therapy for prevention and treatment, added Cap.

Scientists believe monoclonal antibodies—derived from a single immune cell—may also hold potential as both a treatment and preventive measure against COVID-19. Krebs and her team have engineered monoclonal antibodies in the lab by isolating the best neutralizing antibodies from CCP samples to create an army of exact replicas that target the COVID-19 virus down to the atomic level, explained Modjarrad. “We know where and how well it’s going to target, and we know the kinetics of how long it will last in the body and how long it will provide protection,” he explained, noting convalescent plasma does not provide that level of effectiveness. “CCP is not generally used for prevention but for treatment.” Monoclonal antibodies could be used for both treatment and prevention of COVID-19 because the transfused neutralizing antibodies would provide immediate immunity, he added.

Monoclonal antibodies have been in use for decades and revolutionized cancer treatment. Krebs’ lab plans to expand the research into monoclonal antibodies against COVID-19 into animal studies this summer. “Our primary goal is to come up with a treatment for people who have COVID-19,” she said.

Anyone able to donate convalescent plasma should contact the Armed Services Blood Program or go online to find a complete list of available collection centers.

You also may be interested in...

Printable VAX Fact Getting COVID and Flu Vaccine at Once

Publication
2/12/2021

This is a printable version of the VAX Fact graphic

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

Printable VAX Fact Where can I get the COVID-19 Vaccine?

Publication
2/12/2021

This is a printable version of the VAX Fact graphic

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

COVID-19 Social Media Toolkit

Publication
1/5/2021

These messages are provided for you to use on your platforms with any of the images from the COVID-19 Toolkit.

Recommended Content:

Coronavirus

COVID-19 Vaccine Toolkit

Publication
1/5/2021

This toolkit provides communicators across the Military Health System (MHS) with important information about the COVID-19 prevention and vaccination from the CDC to share with patients and health care professionals.

Recommended Content:

Coronavirus | COVID-19 Information for Military Treatment Facility Directors | COVID-19 Vaccine Efforts

DoD COVID 19 Vaccine Distribution Plan and Population Schema

Publication
12/10/2020

Regarding the initial COVID-19 vaccination rollout, Defense Department officials announced a phased and coordinated strategic plan for distributing and administering the initial COVID-19 vaccines.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

Holiday Season Guidance to Minimize Spread of the Coronavirus Disease 2019

Publication
11/16/2020

This memorandum provides guidance to help protect individuals within the DoD community from coronavirus disease 2019 (COVID-19) for gatherings and activities during the November to January holiday season.

Recommended Content:

Coronavirus

Updated Guidance for Performing Temperature Checks at Military MTFs and DTFs

Publication
10/21/2020

This guidance is an update to Defense Health Agency Return to Full Operations Concept of Operations, V5.0 (June 12, 2020) as it pertains to temperature checks in MTFs and DTFs. Based on recommendations from the Centers for Disease Control (CDC), previous guidance directed MTFs to take the temperature of all individuals entering the facility. Effective immediately, temperature checks are not required; however, screening of individuals entering MTFs and DTFs and healthcare personnel on duty in the MTF or DTF is to continue.

Recommended Content:

Coronavirus

Force Health Protection Guidance (Supplement 12) -Department of Defense Guidance for Personnel Traveling During the Coronavirus Disease 2019 Pandemic

Publication
8/6/2020

This memorandum supplements requirements in references (a), (b), and (c) with respect to coronavirus disease 2019 (COVID-19), and replaces reference (d). It provides pre- and post­travel guidance for purposes of force health protection (FHP) of Service members, DoD family members, DoD civilian employees, and DoD contractor personnel.

Recommended Content:

Coronavirus

Supplemental Guidance 10 for Military Medical Treatment Facilities and Military Dental Treatment Facilities Directors in regards to Coronavirus Disease 2019

Publication
7/1/2020

Recommended Content:

Coronavirus

Download Letter to Beneficiaries

Publication
6/24/2020

This message replaces guidance issued on March 31. It explains actions military pharmacies are taking to keep services and visits safe during the COVID-19 pandemic, and it outlines your pharmacy options as a TRICARE beneficiary.

Recommended Content:

Coronavirus | COVID Pharmacy Guidance | TRICARE Health Program

Pharmacy Operations Division (POD) Reverse HPCON Status Guidance

Publication
6/24/2020

Guidance for Outpatient MTF Pharmacies in Response to COVID-19

Recommended Content:

Coronavirus | COVID Pharmacy Guidance

Communication to ABA Providers Regarding Continued Temporary Authorization to Utilize Telehealth for CPT Code 97156 During the COVID-19 National Emergency

Publication
6/3/2020

TRICARE is announcing the continuation of the temporary exception to policy regarding the use of synchronous telehealth (TH) capabilities (both audio and video) for Applied Behavior Analysis (ABA) Family Adaptive Behavior Treatment Guidance services specifically during this COVID-19 pandemic.

Recommended Content:

Coronavirus | TRICARE Health Program

Force Health Protection Guidance (Supplement 9) -Department of Defense Guidance for Deployment and Redeployment of Individuals and Units during the Novel Coronavirus Disease 2019 Pandemic

Publication
5/26/2020

This memorandum provides force health protection (FHP) deployment and redeployment guidance for Service members (including Reserve Component (RC) and National Guard members in a title 10 or title 32 duty status) and DoD civilian employees deploying within and outside the United States during the COVID-19 pandemic, consistent with references (a) and (b).

Recommended Content:

Coronavirus

Guidance for Commanders on Risk-Based Changing of Health Protection Condition Levels During the Coronavirus Disease 2019 Pandemic

Publication
5/20/2020

This memorandum provides guidance for commanders to consider when making decisions to change health protection condition (HPCON) levels as COVID-19 pandemic conditions on and adjacent to our installations begin to improve.

Recommended Content:

Coronavirus

Resuming Elective Surgical, Invasive, and Dental Procedures in Military Medical and Dental Treatment Facilities

Publication
5/19/2020

This memorandum provides guidance on how each Military Medical Treatment Facility (MTF) and Dental Treatment Facility (DTF) may resume elective medical and dental procedures.

Recommended Content:

Public Health | Coronavirus
<< < 1 2 3 4 > >> 
Showing results 16 - 30 Page 2 of 4

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.